Cohort I + II | Cohort I | Cohort II | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cases n (%) | Control n (%) | P | OR (95% CI) | Cases n (%) | Controls n (%) | P OR (95% CI) | Cases n (%) | Controls n (%) | P OR (95% CI) | ||
AA 334 (37.7) | 417 (37.9) | 0.885 | – | 233 (38.5) | 276 (35.9) | 0.605 | – | 101 (36.1) | 141 (42.5) | 0.183 | – |
AG 408 (46.1) | 498 (45.2) | – | – | 267 (44.1) | 355 (46.2) | – | – | 141 (50.3) | 143 (43.1) | – | – |
GG 143 (16.2) | 186 (16.9) | – | – | 105 (17.4) | 138 (17.9) | – | – | 38 (13.6) | 48 (14.4) | – | – |
AA/AG 742 (83.8) | 915 (83.1) | 0.661 | 1.06 (0.83–1.34) | 500 (82.6) | 631 (82.1) | 0.776 1.04 (0.79–1.38) | 242 (86.4) | 284 (85.5) | 0.753 1.08 (0.68–1.70) | ||
AG/GG 551(62.3) | 684 (62.1) | 0.951 | 1.01 (0.84–1.21) | 372 (61.5) | 493 (64.1) | 0.318 0.89 (0.72–1.11) | 179 (63.9) | 191 (57.5) | 0.107 1.31 (0.94–1.81) | ||
A 1076 (60.8) | 1332 (60.5) | - 1.00 (reference) | 733 (60.6) | 907 (59.0) | - 1.00 (reference) | 343 (61.3) | 425 (64.0) | - 1.00 (reference) | |||
G 694 (39.2) | 870 (39.5) | 0.847 | 0.99 (0.87–1.12) | 477 (39.4) | 631 (41.0) | 0.394 0.94 (0.80–1.09) | 217 (38.7) | 239 (36.0) | 0.320 1.13 (0.89–1.42) |